ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient in the Phase Ib/II clinical trial of IMM2510 in combination with chemotherapy for the first-line treatment of non-small cell lung cancer was successfully dosed, according to a Monday filing with the Hong Kong bourse.
IMM2510 is a bispecific molecule developed by the group that uses a mAbTrap structure to target two proteins: VEGF, which promotes blood vessel growth, and PD-L1, which suppresses the immune system, reducing blood flow to tumors and leads to their shrinking, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。